The 4G/4G genotype of PAI-1 polymorphism is associated with higher plasma PAI-1 concentrations and mortality in patients with severe sepsis by Lorente, L. et al.
RESEARCH ARTICLE
The 4G/4G Genotype of PAI-1 Polymorphism
Is Associated with Higher Plasma PAI-1
Concentrations and Mortality in Patients with
Severe Sepsis
Leonardo Lorente1*, María M. Martín2, Juan M. Borreguero-León3, Ysamar Barrios4,
Jordi Solé-Violán5, José Ferreres6, Lorenzo Labarta7, César Díaz8, Alejandro Jiménez9
1 Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain,
2 Intensive Care Unit, Hospital Universitario Nuestra Señora Candelaria, Santa Cruz Tenerife, Spain,
3 Laboratory Deparment, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, 4 Laboratory
Deparment of the Research Unit, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife,
Spain, 5 Intensive Care Unit, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain,
6 Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain, 7 Intensive Care Unit,
Hospital San Jorge, Huesca, Spain, 8 Intensive Care Unit, Hospital Insular, Las Palmas de Gran Canaria,
Spain, 9 Statistical Deparment of the Research Unit, Hospital Universitario de Canarias, La Laguna, Santa
Cruz de Tenerife, Spain
* lorentemartin@msn.com
Abstract
Objective
Two studies have reported that patients with the 4G/4G genotype of the plasminogen acti-
vator inhibitor-1 (PAI-1) genetic polymorphism had higher plasma PAI-1 concentrations and
higher risk of death than those with the 4G/5G or 5G/5G genotypes; one study involved 175
children with meningococcal disease, and the other included 88 adult patients with septic
shock. Thus, the objective of this study was to determine whether there is an association be-
tween carriage of the 4G/4G genotype, plasma PAI-1 concentrations and mortality in a
large series of adult septic patients.
Methods
An observational, prospective, multicenter study was carried out in six Spanish Intensive
Care Units including severe septic patients. We determined the PAI-1 4G/5G polymorphism
and plasma PAI-1 concentrations in all patients. The end-points of the study were 30-day
and 6-month mortality.
Results
We included a total of 260 patients, 82 (31.5%) with 4G/4G, 126 (48.5%) with 4G/5G and 52
(20.0%) with 5G/5G genotype. Multivariate logistic regression analysis showed that the 4G/4G
genotype was associated with higher mortality at 30 days (Odds Ratio = 1.95; 95%CI = 1.063–
3.561; p = 0.03) and at 6 months (Odds Ratio = 2.19; 95%CI = 1.221–3.934; p = 0.01), and
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that higher plasma PAI-1 concentrations were associated with higher mortality at 30 days
(Odds Ratio = 1.01; 95%CI = 1.002–1.022; p = 0.02) at 6 months (Odds Ratio = 1.01; 95%
CI = 1.003–1.023; p = 0.01). Multivariate linear regression analysis showed that increased
plasma PAI-1 concentrations were associated with the PAI-1 4G/4G genotype (regression co-
efficient = 4.82; 95%CI = 3.227 to 6.406; p<0.001).
Conclusions
The major findings of our study, to our knowledge the largest series reporting data about
4G/5G polymorphism of the PAI-1 gene, plasma PAI-1 concentrations and mortality in sep-
tic patients, were that septic patients with the 4G/4G genotype had higher plasma PAI-1
concentrations and higher risk of death than those with 4G/5G or 5G/5G genotypes.
Introduction
Sepsis represents a systemic response of the immune system to infection, which is a common,
expensive, and frequently fatal condition. During sepsis, the pro-coagulant and anti-fibrinolyt-
ic pathways lead to microvascular fibrin deposition, resulting in multi-organ failure, and ulti-
mately death. [1].
Plasminogen activator inhibitor-1 (PAI-1) plays an important role in the fibrinolytic re-
sponse [2]. Previous studies have found higher plasma PAI-1 concentrations in non-surviving
than in surviving septic patients [3–12]. In addition, the association between PAI-1 4G/5G
polymorphism and mortality in septic patients has been studied [10–20]. Some authors report
that patients with the 4G/4G genotype of the PAI-1 gene had higher mortality rates than pa-
tients with other genotypes [10–14]; however, this was not found in other studies [15–20]. A
recently published meta-analysis [21], including most of those studies [10–19], found that pa-
tients with the 4G/4G genotype of the PAI-1 gene had a higher risk of death than patients with
4G/5G or 5G/5G genotypes. However, only 3 of those studies also measured plasma PAI-1 con-
centrations [10–12]. Two studies have reported that patients with the 4G/4G genotype of the
PAI-1 gene had higher plasma PAI-1 concentrations and higher risk of death than those with
the 4G/5G or 5G/5G genotypes; one study involved 175 children with meningococcal disease
[10], and the other included 88 adult patients with septic shock [11]. Another study with 166
adult septic patients reported that patients with the 4G/4G genotype and that patients with
higher plasma PAI-1 concentrations had a higher risk of death; however, an association be-
tween PAI-1 4G/5G polymorphism and plasma PAI-1 concentrations was not reported [12].
Thus, the objective of this study was to determine whether there is an association between car-
riage of the PAI-1 4G/4G genotype, plasma PAI-1 concentrations and mortality in a large series
of adult septic patients.
Materials and Methods
Design and Subjects
Amulticenter, cohort study was carried out in 260 patients with severe sepsis from six Spanish
Intensive Care Units. The study was approved by the Institutional Review Boards of the six
participating hospitals: Hospital Universitario de Canarias (La Laguna. Santa Cruz de Tenerife.
Spain), Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife. Spain),
Hospital Universitario Dr. Negrín (Las Palmas de Gran Canaria. Spain), Hospital Clínico
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Universitario de Valencia (Valencia. Spain), Hospital San Jorge (Huesca. Spain) and Hospital
Insular (Las Palmas de Gran Canaria. Spain). Written informed consent from the patients or
from their family members was obtained.
The diagnosis of severe sepsis was established according to the International Sepsis Defini-
tions Conference [22]. Exclusion criteria were: age<18 years, pregnancy, lactation, human
immunodeficiency virus (HIV), white blood cell count<1,000/mm3, solid or hematologic tu-
mour, or immunosuppressive, steroid or radiation therapy.
Variables recorded
The following variables were recorded for each patient: age, sex, diabetes mellitus, ischemic heart
disease, chronic obstructive pulmonary disease (COPD), Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [23], activated partial thromboplastin time (aPTT), empiric an-
timicrobial treatment, bilirubin, bloodstream infection, creatinine, international normalized ratio
(INR), lactic acid, leukocytes, microorganism responsible, pressure of arterial oxygen/fraction in-
spired of oxygen (PaO2/FiO2), platelets, site of infection, and Sepsis-related Organ Failure Assess-
ment [SOFA] score [24]. The end-points of the study were 30-day and 6-month mortality.
Blood samples
Blood samples were collected from patients at the time severe sepsis was diagnosed. Venous
blood samples were placed in citrated plasma tubes and centrifuged within 30 minutes at
1000g for 15 minutes, and frozen at -80°C until the determination of PAI-1 concentration. In
addition, venous blood were placed in EDTA-containing tubes and frozen at -80°C until deter-
mination of genetic polymorphism of PAI-1.
Gene analysis
Gene analysis was centralized at the Research Unit of the Hospital Universitario de Canarias
(La Laguna. Tenerife. Spain). Venous blood samples in EDTA-containing tubes were subjected
to DNA purification using proteinase K, phenol-chloroform extraction, and ethanol precipita-
tion. Genotyping was performed in a blinded manner, without knowledge of any clinical data.
PAI-1 4G/5G polymorphism was determined for all patients using primers and restriction en-
donuclease digestion. In addition, 22 neutral markers were genotyped to follow genomic con-
trol strategies that would detect spurious associations due to population substructure. The
neutral markers chosen were Alu repeats distributed throughout the genome.
Plasma PAI-1 level assay
The assay of plasma PAI-1 concentrations was centralized at the Laboratory Department of the
Hospital Universitario de Canarias (La Laguna. Tenerife. Spain). PAI-1 antigen was assayed by
specific ELISA (Imubind Plasma PAI-1 Elisa. American Diagnostica, Inc., Stanford, CT, USA)
according to the manufacturer's instructions. The assay detects latent (inactive) and active
forms of PAI-1 and PAI-1 complexes. The interassay coefficient of variation (CV) was<5%
(n = 20) and the detection limit for the assay was 1 ng/ml.
Statistical Methods
Continuous variables are reported as medians and interquartile ranges. Categorical variables
are reported as frequencies and percentages. Comparisons of continuous variables between
groups were carried out using Wilcoxon-Mann-Whitney test. Comparisons between groups of
categorical variables were carried out with chi-square test. Multivariate logistic regression
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analysis was applied to determine the independent contribution of PAI-1 4G/5G polymor-
phism on 30-day and 6-month mortality, after controlling for diabetes mellitus, ischemic heart
disease, COPD, age, SOFA score and serum lactic acid concentrations. Odds ratio (OR) and
95% confidence intervals (CI) were calculated as measurement of the clinical impact of the pre-
dictor variables. We used linear regression modelling to analyze the relationship between plas-
ma PAI-1 concentrations as the dependent variable, and 4G/5G polymorphism, diabetes
mellitus, ischemic heart disease and COPD as independent variables. Regression coefficients
and 95% CI were calculated as measurement of the clinical impact of the predictor variables.
Survival curves at 30 days and 6 months, using 4G/4G vs other genotypes of PAI-1 gen, were
plotted using the Kaplan-Meier method and compared by log-rank test. We used Chi-square
to test Hardy-Weinberg equilibrium among our genotypes. A P value of less than 0.05 was con-
sidered statistically significant. Statistical analyses were performed with SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA) and NCSS 2000 (Kaysville, Utah).
Results
We included a total of 260 patients with severe sepsis; 82 (31.5%) with genotype 4G/4G, 126
(48.5%) with genotype 4G/5G and 52 (20.0%) with genotype 5G/5G of the PAI-1 gene. We
found no significant deviation from Hardy-Weinberg equilibrium among our genotypes (Chi-
square = 0.08; p = 0.78)
As shown in Table 1, there were no significant differences between different genotypes in
gender, age, diabetes mellitus, ischemic heart disease, CRF, site of infection, microorganism re-
sponsible, bloodstream infection, septic shock, empiric antimicrobial treatment, PaO2/FIO2,
creatinin, bilirubin, leukocytes count, INR, APACHE-II score and SOFA score. However, pa-
tients with the 4G/4G genotype showed higher lactatemia, aPTT, and plasma PAI-1 concentra-
tions, and lower platelet count and COPD rate than patients with other genotypes. In addition,
patients with the 4G/4G genotype showed higher 30-day and 6-month mortality than patients
with other genotypes (Table 2). In addition, we have not found statistically significant differ-
ences in 30-day (p = 0.53) and 6-month (p = 0.42) mortality rate between the different ICUs.
Multiple logistic regression analysis showed that the 4G/4G genotype was associated with
higher mortality at 30 days (Odds Ratio = 1.95; 95% CI = 1.063–3.561; p = 0.03) and at 6
months (Odds Ratio = 2.19; 95% CI = 1.221–3.934; p = 0.01), after controlling for diabetes mel-
litus, ischemic heart disease, COPD, age, SOFA score and serum lactic acid concentrations (Ta-
bles 3 and 4). In addition, multiple logistic regression analysis showed that plasma PAI-1
concentrations were associated with higher mortality at 30 days (Odds Ratio = 1.01; 95%
CI = 1.002–1.022; p = 0.02) and at 6 months (Odds Ratio = 1.01; 95% CI = 1.003–1.023;
p = 0.01), after controlling for diabetes mellitus, ischemic heart disease, COPD, age, SOFA
score and serum lactic acid concentrations (Tables 3 and 4).
Multivariate linear regression analysis showed that plasma PAI-1 concentrations were asso-
ciated with PAI-1 4G/5G polymorphism, after controlling for diabetes mellitus, ischemic heart
disease and COPD (regression coefficient = 4.82; 95% CI = 3.227 to 6.406; p<0.001) (Table 5).
Survival analysis showed that patients with the PAI-1 4G/4G genotype presented lower
30-day survival (Chi-square = 8.82; Hazard ratio = 1.9 (95% CI = 1.17–2.95); p = 0.003) and
lower 6-month survival (Chi-square = 8.82; p = 0.003) than those with other genotypes (Chi-
square = 11.4; Hazard ratio = 1.9 (95% CI = 1.24–2.88); p<0.001) (Fig 1).
Discussion
To our knowledge, this is the largest study to date reporting data about PAI-1 4G/5G polymor-
phism, plasma PAI-1 concentrations and mortality in septic patients. The major findings of
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Table 1. Characteristics of severe septic patients according to genotype in the PAI-1 gene.
4G/4G
(n = 82)
4G/5G
(n = 126)
5G/5G
(n = 52)
4G/5G more 5G/5G
(n = 178)
P-value 4G/4G vs
others
Gender female–n (%) 30 (36.6) 44 (34.9) 16 (30.8) 60 (33.7) 0.68
Age—median years (percentile 25–75) 63 (50–74) 60 (48–70) 57 (46–68) 58 (47–69) 0.37
Diabetes Mellitus–n (%) 21 (25.6) 36 (28.6) 16 (30.8) 52 (29.2) 0.66
COPD–n (%) 4 (4.9) 19 (15.1) 8 (15.4) 27 (15.2) 0.02
Ischemic heart disease–n (%) 11 (13.4) 15 (11.9) 4 (7.7) 19 (10.7) 0.54
Site of infection–n (%) 0.52
Respiratory 42 (51.2) 76 (60.3) 26 (50.0) 102 (57.3)
Abdominal 31 (37.8) 35 (27.8) 12 (23.1) 47 (26.4)
Neurological 1 (1.2) 1 (0.8) 3 (5.8) 4 (2.2)
Urinary 4 (4.9) 3 (2.4) 4 (7.7) 7 (3.9)
Skin 2 (2.4) 5 (4.0) 4 (7.7) 9 (5.1)
Endocarditis 2 (2.4) 5 (4.0) 3 (5.8) 8 (4.5)
Osteomyelitis 0 1 (0.8) 0 1 (0.6)
Microorganism responsibles–n (%)
Unkwon 44 (53.7) 62 (49.2) 29 (55.8) 91 (51.1) 0.79
Gram-positive 19 (23.2) 35 (27.8) 9 (17.3) 44 (24.7) 0.88
Gram-negative 20 (24.4) 31 (24.6) 12 (23.1) 43 (24.2) 0.99
Fungii 3 (3.7) 1 (0.8) 3 (5.8) 4 (2.2) 0.68
Anaerobe 2 (2.4) 1 (0.8) 0 1 (0.6) 0.24
Bloodstream infection–n (%) 15 (18.3) 17 (13.5) 8 (15.4) 25 (14.0) 0.46
Empiric antimicrobial treatment–n (%) 0.73
Unkown if adequate due to negative cultures 43 (52.4) 63 (50.0) 29 (55.8) 92 (51.7)
Unkown if adequate due to diagnosis by
antigenuria
2 (2.4) 3 (2.4) 1 (1.9) 4 (2.2)
Adequate 35 (42.7) 52 (41.3) 20 (38.5) 72 (40.4)
Inadequate 2 (2.4) 8 (6.3) 2 (3.8) 10 (5.6)
Betalactamic more aminoglycoside–n (%) 18 (22.0) 30 (23.8) 14 (26.9) 44 (24.7) 0.75
Betalactamic more quinolone–n (%) 43 (52.4) 63 (50.0) 29 (55.8) 92 (51.7) 0.99
Septic shock–n (%) 72 (87.8) 105 (83.3) 45 (86.5) 150 (84.3) 0.57
Pa02/FI02 ratio—median (percentile 25–75) 194 (104–279) 183 (118–253) 152 (101–253) 180 (114–250) 0.99
Creatinine (mg/dl)—median (percentile 25–75) 1.30 (0.90–
2.20)
1.30 (0.80–
2.35)
1.45 (0.80–
2.60)
1.40 (0.80–2.40) 0.97
Bilirubin (mg/dl)—median (percentile 25–75) 0.90 (0.50–
2.55)
0.88 (0.40–
1.64)
1.15 (0.50–
1.73)
0.90 (0.44–1.70) 0.62
Leukocytes (cells/mm3)—median*103
(percentile 25–75)
14.0 (8.1–
22.5)
14.9 (8.6–
19.7)
16.0 (10.2–
22.3)
15.1 (9.6–20.4) 0.61
Lactic acid (mmol/L)—median (percentile 25–
75)
3.20 (1.50–
4.65)
1.80 (1.05–
4.10)
2.00 (1.18–
3.57)
2.00 (1.10–4.00) 0.004
Platelets (cells/mm3)—median*103 (percentile
25–75)
156 (82–237) 190 (119–271) 186 (97–255) 190 (117–266) 0.050
INR—median (percentile 25–75) 1.36 (1.11–
1.68)
1.29 (1.09–
1.51)
1.34 (1.16–
1.62)
1.33 (1.10–1.51) 0.29
aPTT (seconds)—median (percentile 25–75) 36 (30–44) 32 (28–44) 32 (27–44) 32 (28–44) 0.03
APACHE-II score- median (percentile 25–75) 21 (17–25) 20 (16–25) 20 (15–24) 20 (15–24) 0.32
SOFA score—median (percentile 25–75) 9 (7–13) 9 (7–12) 10 (8–12) 9 (7–12) 0.34
(Continued)
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our study were that septic patients with the 4G/4G genotype had higher plasma PAI-1 concen-
trations and higher risk of death than those with 4G/5G or 5G/5G genotype.
Previous studies have found higher plasma PAI-1 concentrations in septic patients than in
controls [25–28], and higher plasma PAI-1 concentrations in non-surviving than in surviving
septic patients [3–12]. In addition, patients with the PAI-1 4G/4G genotype had a higher risk
of death than patients with the 4G/5G or 5G/5G genotypes, according to a recently published
meta-analysis [21]. In one study involving 175 children with meningococcal disease [10] and
another with 88 adult septic shock patients [11], it was found that patients with the 4G/4G ge-
notype of the PAI-1 gene had higher plasma PAI-1 concentrations and higher risk of death
than those with the 4G/5G or 5G/5G genotypes. In addition, another study that included 166
adult patients with sepsis reported that patients with the 4G/4G genotype and those with
higher plasma PAI-1 concentrations had a higher risk of death; however, the association be-
tween PAI-1 4G/5G polymorphism and plasma PAI-1 concentrations was not reported [12].
García-Segarra et al [11] and Wingeyer et al [12] carried out a regression analysis to determine
the independent contribution of PAI-1 4G/5G polymorphism on 30-day mortality; but this
was not done in the study by Hermans et al [10]. In our study, patients with the PAI-1 4G/4G
genotype showed higher mortality at 30 days and at 6 months on multiple logistic regression
analysis, and that plasma PAI-1 concentrations were associated with the PAI-1 4G/5G poly-
morphism on linear regression analysis (not reported in previous studies).
The frequencies of the PAI-1 genotypes in our septic patients (31.5% with 4G/4G, 48.5%
with 4G/5G and 20.0% with 5G/5G genotype) are similar to those found in the meta-analysis
by Li et al (30.8% with 4G/4G, 47.2% with 4G/5G and 22.0% with the 5G/5G genotype) [21].
During sepsis there is coagulation activation and fibrinolysis inhibition, contributing to cap-
illary thrombosis, multiple organ dysfunction, and finally death. PAI-1 is a member of the ser-
ine protease inhibitor (serpin) family, which regulates fibrinolysis by inhibiting the tissue-type
plasminogen activator (t-PA) and the urokinase-type plasminogen activator (u-PA) [2]. PAI-1
plays an important role in the down-regulation of fibrinolysis during sepsis [29]. Consequently,
high concentrations of PAI-1 contribute to multiple organ dysfunction, and thus, increase the
risk of death. We believe that the higher mortality observed in patients with the 4G/4G geno-
type was related with their higher plasma PAI-1 concentrations, and this may have favoured
the appearance of capillary thrombosis, which in turn could have led to multiple organ dys-
function, and finally death.
Table 1. (Continued)
4G/4G
(n = 82)
4G/5G
(n = 126)
5G/5G
(n = 52)
4G/5G more 5G/5G
(n = 178)
P-value 4G/4G vs
others
PAI-1 levels (ng/mL)—median (percentile 25–
75)
60.3 (38.5–
81.0)
36.2 (20.0–
64.7)
28.2 (17.4–
63.4)
33.1 (18.6–63.6) <0.001
COPD = chronic obstructive pulmonary disease; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; INR = International normalized ratio
aPTT = Activated partial thromboplastin time; APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sepsis-related Organ Failure
Assessment.
doi:10.1371/journal.pone.0129565.t001
Table 2. Early and late mortality according to genotype in the PAI-1 genetis polymorphis.
4G/4G (n = 82) 4G/5G (n = 126) 5G/5G (n = 52) 4G/5G or 5G/5G (n = 178) P-value 4G/4G vs others
30-day mortality—n (%) 37 (45.1) 36 (28.6) 16 (30.8) 52 (29.2) 0.02
6-month mortality—n (%) 45 (54.9) 43 (34.1) 21 (40.4) 64 (35.9) 0.01
doi:10.1371/journal.pone.0129565.t002
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Therefore, a possible approach for the treatment of severe sepsis could be the control of
PAI-1 activity in order to modulate fibrinolysis to avoid organ dysfunction and thus decrease
the mortality rate. Some strategies have also been found to inhibit the PAI-1 activity in in vitro
models [30–35] and in animal models [36–38]. However, to date there are no studies reporting
the clinical application of PAI-1 inhibitors in septic patients. Thus, more research is necessary
before the inhibition of PAI-1 can be considered a novel therapy for septic patients.
We think that the determination of the PAI-1 4G/5G polymorphism could help in the selec-
tion of patients who have more risk of death. The strengths of our study are the large sample
size (n = 260), the fact that it was a multicenter study, and that we carried out linear regression
Table 3. Multiple logistic regression analyses to predict 30-daymortality.
Odds Ratio 95% Confidence Interval P-value
FIRST MODEL
Genotype of PAI-1 gene (4G/4G vs other) 1.95 1.063–3.561 0.03
Diabetes Mellitus (yes vs non) 2.16 1.160–4.028 0.02
Chronic obstructive pulmonary disease (yes vs non) 1.07 0.434–2.649 0.88
Ischemic heart disease (yes vs non) 0.56 0.220–1.440 0.23
SOFA (points) 1.15 1.056–1.249 0.001
Lactic acid levels (mmol/L) 1.13 1.020–1.247 0.02
Age (years) 1.02 0.998–1.039 0.08
SECOND MODEL
Plasma PAI-1 levels (ng/mL) 1.01 1.002–1.022 0.02
Diabetes Mellitus (yes vs non) 2.05 1.097–3.835 0.02
Chronic obstructive pulmonary disease (yes vs non) 0.94 0.385–2.311 0.90
Ischemic heart disease (yes vs non) 0.62 0.244–1.578 0.32
SOFA (points) 1.14 1.044–1.236 0.003
Lactic acid levels (mmol/L) 1.09 0.984–1.211 0.10
Age (years) 1.02 0.997–1.038 0.10
doi:10.1371/journal.pone.0129565.t003
Table 4. Multiple logistic regression analyses to predict 6-monthmortality.
Odds Ratio 95% Confidence Interval P-value
FIRST MODEL
Genotype of PAI-1 gene (4G/4G vs other) 2.19 1.221–3.934 0.01
Diabetes Mellitus (yes vs non) 1.88 1.025–3.437 0.04
Chronic obstructive pulmonary disease (yes vs non) 1.70 0.726–3.969 0.22
Ischemic heart disease (yes vs non) 0.75 0.314–1.794 0.52
SOFA (points) 1.11 1.027–1.207 0.01
Lactic acid levels (mmol/L) 1.15 1.035–1.278 0.01
Age (years) 1.01 0.994–1.033 0.18
SECOND MODEL
Plasma PAI-1 levels (ng/mL) 1.01 1.003–1.023 0.01
Diabetes Mellitus (yes vs non) 1.78 0.969–3.270 0.06
Chronic obstructive pulmonary disease (yes vs non) 1.47 0.636–3.390 0.37
Ischemic heart disease (yes vs non) 0.83 0.351–1.966 0.67
SOFA (points) 1.10 1.015–1.192 0.02
Lactic acid levels (mmol/L) 1.11 0.994–1.234 0.06
Age (years) 1.01 0.993–1.032 0.20
doi:10.1371/journal.pone.0129565.t004
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modelling to analyze the relationship between plasma PAI-1 concentrations and 4G/5G poly-
morphism, after controlling for other variables. On the other hand, the study has certain limita-
tions. First, we did not determine PAI-1 genetic polymorphisms in healthy control subjects
and in non-septic critically ill patients; however, the objective of our study was not to deter-
mine the association between the polymorphism and the occurrence of sepsis, but rather the
association between the polymorphism and sepsis survival. Second, we did not analyse other
genes and a gene-gene interaction is possible [39,40]. Thus, although the 4G/4G genotype
seems to be associated with increased plasma PAI-1 concentrations and mortality, new studies
with large sample sizes are needed to determine whether there is some gene-gene interaction
that affects the prognosis of septic patients. Third, most of our patients were from the Canary
Islands and the results may not be generalizable to other populations. Fourth, we found that
carriage of the PAI-1 4G/4G genotype was associated with higher mortality after controlling
for diabetes mellitus, ischemic heart disease, COPD, age, SOFA score and serum lactic acid
concentrations; however other factors could have played a role in this.
Table 5. Lineal multivariate regression analysis to predict plasma PAI-1 levels.
Regression coefficient 95% Confidence Interval P-value
Genotype of PAI-1 gene (4G/4G vs other) 4.82 3.227 to 6.406 <0.001
Diabetes Mellitus 4.84 -3.410 to 13.090 0.25
Chronic obstructive pulmonary disease 0.53 -10.951 to 12.005 0.93
Ischemic heart disease 2.52 -14.208 to 9.178 0.67
doi:10.1371/journal.pone.0129565.t005
Fig 1. Kaplan-Meier curves showing the cumulative proportion of survival patients at 30 days and 6
months according to the presence of 4G/4G vs other genotypes of PAI-1 genetic polymorphism.
doi:10.1371/journal.pone.0129565.g001
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Conclusions
To our knowledge, this is the largest study to date reporting data about PAI-1 4G/5G polymor-
phism, plasma PAI-1 concentrations and mortality in septic patients. The major findings of
our study were that septic patients with the 4G/4G genotype had higher plasma PAI-1 concen-
trations and higher risk of early death than those with the 4G/5G or 5G/5G genotype.
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